- Base year considered - 2019
- Actual estimates/Historical data - 2014- 2018
- Forecast period - 2019- 2029
- Forecast units - Value (USD) Mn
- Segments covered - Test Type, End User, and Region
- Regions covered - North America (US & Canada), Western Europe (UK, Germany, France, Spain, Italy, Rest of Western Europe), Eastern Europe( Russia & Rest of Eastern Europe), Latin America (Brazil, Mexico, and Rest of LA), APEJ (China, India, A&NZ and Rest of APEJ), and MEA (GCC, South Africa, and Rest of MEA)
- Key Players - Thermo Fisher Scientific, Inc, Roche Molecular Systems Inc., bioMérieux SA, Abbott Laboratories, InBios International, Inc., NovaTec Immundiagnostica GmbH, Euroimmun AG (Sub. PerkinElmer), Quest Diagnostics, Certest Biotec S.L., Response Biomedical Corp, and Chembio Diagnostic Systems Inc.
- Report coverage - Revenue forecasts, competitive landscape, growth factors, and trends
ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET - KEY RESEARCH FINDINGS
- By 2029, the Arthropod-borne viral infections testing market size will reach around US$ 2 Bn.
- The Arthropod-borne viral infections testing market is anticipated to expand at a CAGR of 6% during the forecast period of 2019-2029.
- ELISA-based tests would be the preferred test type in the Arthropod-borne viral infections testing market.
- Growth of this particular segment can be primarily attributed to the rising interest and acceptance of ELISA-based test diagnostics in developing countries.
- Latin America is stipulated to account for around 21% of the global Arthropod-borne viral infections testing market revenue by 2029.
- The Latin America market continues to offer lucrative prospects to Arthropod-borne viral infections testing providers, given the increasing Arthropod-borne viral infections and testing techniques used in healthcare institutions for providing quality care. This has further resulted in increased adoption of molecular-based techniques such as ELISA and RT-PCR.
- Public healthcare laboratories will remain the prominent end-use category in the Arthropod-borne viral infections testing market.
- Increasing access to advanced healthcare in developed public healthcare laboratories employing advanced molecular techniques for quick detection of Arthropod-borne viral pathogens is among the major factors propelling the Arthropod-borne viral infections testing market.
KEY FACTORS SHAPING ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET
Re-emergence of Arthropod-borne Viral Infections
- Disordered urban growth, environmental changes due to changing lifestyle, and globalization are major causes of the dissemination and emergence of Arthropod-borne viral infections.
- Reemergence of the viral infection has caused widespread epidemics of human and animal diseases, making them more unpredictable. This has resulted in sporadic outbreaks in Latin America.
- For instance, Brazilian national authorities estimate that, between 497,593 and 1,482,701 cases of Zika virus infections have been reported since the outbreak. After Brazil, Colombia has been the most-affected country so far, with 20,297 cases reported (Jan 2016) since the country’s first case detected in October 2015.
Integrated Government Initiatives
Arboviruses are an emerging threat in Europe. Rising infection rates driven by increasing global trade and travel has fueled the adoption of Arthropod-borne viral infections testing in new geographies.
- Because of the increasing threat, the European Centre for Disease Prevention and Control (ECDC) started an integrated control strategy against invasive Arthropod-borne vectors, with coordinated involvement of local authorities, private partners, and organized societies.
- This initiative mainly focuses on public education, vector control, and period diagnosis in infection prone areas.
- ECDC also provides vector distribution maps and step-by-step guidelines for the surveillance of invasive mosquitos, to raise awareness among the population.
In a bid to break the pattern of the coronavirus (COVID-19) pandemic across the globe, governments are showing immediacy in approving diagnostic tests to treat affected patients. A majority of these tests are based on enzyme-linked immunosorbent assays (ELISA) - that offer faster results - and reverse transcription polymerase chain reaction (RT-PCR) - the current standard approach for COVID-19. Increasing cases and uncertainties regarding COVID-19 have offered an additional wave of growth to players in the Arthropod-borne viral infections testing market.
ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET: COMPLETION ANALYSIS
- The Arthropod-borne viral infections testing market is highly competitive. Approximately 10 Arthropod-borne viral infections testing providers are present globally. Tier-1 players lead the market with around 50% revenue share.
- In high-impact markets such as Latin America, East Asia, and South Asia, there are stringent regulations for the approval of Arthropod-borne viral infections testing procedures. However, incumbents developing new testing methods will help achieve regulatory compliance rapidly. These tests have already been made operational in low-risk regions in the US, Canada, and some nations in Europe. Such developments will help in facilitating secure exchange ideas for product development, and thus, protect overall patient safety and other challenges.
- Some of the key players are mainly focused on developing diagnostics based on microarray technology. The technology majorly consists of detecting nucleic acid fragments of different pathogens.
- Some the leading players in the Arthropod-borne viral infections testing market are Thermo Fisher Scientific, Inc, Roche Molecular Systems Inc., bioMérieux SA, and Abbott Laboratories
- Arthropod-borne viral infections testing market players are also focused on emerging markets such as India, China, and Brazil, owing to their significant marketing network of distributors. Moreover, due to strategic partnerships and tie-ups with local sales bodies and the presence of international offices in other regions, major players could deliver their services and solution offerings to retain their customer base.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Arthropod-borne Viral Infections Testing Market Analysis by Test Type
Enzyme-linked immunosorbent assay (ELISA)-based tests are considered a preferred laboratory tool among researchers and professionals in sectors such as healthcare, life sciences, and industries, as the testing method is sensitive, specific, economical, and reliable. By 2029, realization from ELIS-based tests would reach near US$ 1 Bn.
The autoimmunity immunoassay field is transforming, and in the recent past, the development of no wash ELISAs, reduced assay step protocols, and new automated systems designed to run ELISA-based tests have entered the laboratories. Moving forward, healthcare diagnostic testing market players will also capitalize on reverse-transcription polymerase chain reaction (RT-PCR) kits, owing to their better turnaround time (3-4 hours).
Arthropod-borne Viral Infections Testing Market Regional Assessment
The Middle East & Africa (MEA) and Latin America would remain the epicenter of value-creation opportunities. While both these regions share almost equal divide in the global Arthropod-borne viral infections testing market, players would cite MEA for substantial profits. Alarmed by the expanding patient pool of Arthropod-borne viral infections, governments in MEA and Latin America are increasingly spending on the healthcare industry in order to deliver quality-focused care. Going forward, the Asia Arthropod-borne viral infections testing market will also offer potential revenue lines to investors.
Government-backed Initiatives to Augur Well for Market Growth
Arboviruses are considered an emerging threat across several regions, worldwide. Rise in global trade and travel activities are responsible for the emergence of Arthropod-borne viral infections in new geographies. Alerted by the possible threat, government agencies such as the European Centre for Disease Prevention and Control (ECDC) have initiated the integrated control strategy against invasive Arthropod-borne vectors with the coordinated involvement of local authorities, private partners, and organized societies.
The initiative is primarily focused on vector control, public education, and period diagnosis in infectioniprone regions. In addition, ECDC offers vector distribution maps and guidelines for the surveillance of invasive mosquitos to raise awareness among demographics. Such government-backed initiatives will drive the growth of the Arthropod-borne viral infections testing market.
How Growth will Unfold
Public healthcare laboratories would remain the primary end user of Arthropod-borne viral infections testing, owing to increasing investments in advanced healthcare equipped with viral molecular diagnostic techniques. Capturing around one-third of overall market value, market players continue to allocate their resources to public healthcare laboratories. On the other hand, diagnostic centers are also attracting stakeholders’ investments. While both, public healthcare laboratories and diagnostic centers exhibit similar CAGRs, the former would remain a key revenue pocket.
ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET TAXONOMY
The global Arthropod-borne viral infections testing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the readers.
- ELISA-based Tests
- RT-PCR-based Tests
- Immunochromatography Rapid Diagnosis
- Public Health Laboratories
- Diagnostic Centers
- North America
- Latin America
- Western Europe
- Eastern Europe